158 related articles for article (PubMed ID: 38264842)
1. Steroid-dependent polyarthritis induced by immune checkpoint inhibitor therapy successfully treated with bimekizumab.
Springer R; Lange K; Homey B; Meller S; Lindhof HH
Immunotherapy; 2024 Mar; 16(5):287-293. PubMed ID: 38264842
[TBL] [Abstract][Full Text] [Related]
2. Successful use of secukinumab in two melanoma patients with immune checkpoint inhibitor-induced inflammatory arthropathy.
Ma VT; Lao CD; Fecher LA; Schiopu E
Immunotherapy; 2022 Jun; 14(8):593-598. PubMed ID: 35416067
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitor-induced refractory polyarthritis rapidly improved by sarilumab and monitoring with joint ultrasonography: A case report.
Abe K; Ishikawa Y; Fujiwara M; Yukawa H; Yanagihara T; Takei S; Arioka H; Kita Y
Medicine (Baltimore); 2022 Jan; 101(2):e28428. PubMed ID: 35029182
[TBL] [Abstract][Full Text] [Related]
4. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
[TBL] [Abstract][Full Text] [Related]
5. Steroid-refractory dermatologic and pulmonary toxicity in a patient on rituximab treated with pembrolizumab for progressive urothelial carcinoma: a case report.
Hines J; Daily E; Pham AK; Shea CR; Nadeem U; Husain AN; Stadler WM; Reid P
J Med Case Rep; 2021 Mar; 15(1):124. PubMed ID: 33736690
[TBL] [Abstract][Full Text] [Related]
6. Perspectives on Psoriasiform Adverse Events from Immune Checkpoint Inhibitors: Lessons Learned from Our Practice.
Popa LG; Giurcaneanu C; Portelli MG; Mihai MM; Beiu C; Orzan OA; Ion A; Anghel TH
Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541099
[No Abstract] [Full Text] [Related]
7. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
[TBL] [Abstract][Full Text] [Related]
8. Bimekizumab for the treatment of psoriasis.
Thapar M; Patel M; Gordon K
Immunotherapy; 2024 Apr; 16(7):431-446. PubMed ID: 38506262
[TBL] [Abstract][Full Text] [Related]
9. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
[TBL] [Abstract][Full Text] [Related]
10. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.
Reynolds KL; Guidon AC
Oncologist; 2019 Apr; 24(4):435-443. PubMed ID: 30482825
[TBL] [Abstract][Full Text] [Related]
12. Delayed immune-related neutropenia with hepatitis by pembrolizumab.
Nakako S; Nakashima Y; Okamura H; Tani Y; Ueda T; Makuuchi Y; Kuno M; Takakuwa T; Nishimoto M; Koh H; Nakamae H; Hino M
Immunotherapy; 2022 Feb; 14(2):101-105. PubMed ID: 34758635
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitor-induced inflammatory arthritis: identification and management.
Williams SG; Mollaeian A; Katz JD; Gupta S
Expert Rev Clin Immunol; 2020 Aug; 16(8):771-785. PubMed ID: 32772596
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series.
Kim ST; Tayar J; Trinh VA; Suarez-Almazor M; Garcia S; Hwu P; Johnson DH; Uemura M; Diab A
Ann Rheum Dis; 2017 Dec; 76(12):2061-2064. PubMed ID: 28830882
[TBL] [Abstract][Full Text] [Related]
15. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.
Papp KA; Merola JF; Gottlieb AB; Griffiths CEM; Cross N; Peterson L; Cioffi C; Blauvelt A
J Am Acad Dermatol; 2018 Aug; 79(2):277-286.e10. PubMed ID: 29609013
[TBL] [Abstract][Full Text] [Related]
16. Case Report: Glucocorticoid Effect Observation in a Ureteral Urothelial Cancer Patient With ICI-Associated Myocarditis and Multiple Organ Injuries.
Hu X; Wei Y; Shuai X
Front Immunol; 2021; 12():799077. PubMed ID: 34975911
[TBL] [Abstract][Full Text] [Related]
17. Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients.
Nikolaou VA; Apalla Z; Carrera C; Fattore D; Sollena P; Riganti J; Segura S; Freites-Martinez A; Lallas K; Romano MC; Oikonomou C; Starace M; Dimopoulos MA; Kyrgidis A; Lazaridou E; Giavedoni P; Annunziata MC; Peris K; Echeverría M; Lopez-Tujillo E; Syrigos K; Papageorgiou C; Podlipnik S; Fabbrocini G; Torre AC; Kemanetzi C; Villa-Crespo L; Lallas A; Stratigos AJ; Sibaud V
Br J Dermatol; 2022 Dec; 187(6):962-969. PubMed ID: 35861701
[TBL] [Abstract][Full Text] [Related]
18. Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors.
Skribek M; Rounis K; Afshar S; Grundberg O; Friesland S; Tsakonas G; Ekman S; De Petris L
Eur J Cancer; 2021 Mar; 145():245-254. PubMed ID: 33419647
[TBL] [Abstract][Full Text] [Related]
19. Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Melanoma.
Pepys J; Stoff R; Ramon-Gonen R; Ben-Betzalel G; Grynberg S; Frommer RS; Schachter J; Asher N; Taliansky A; Nikitin V; Dori A; Shelly S
Neurology; 2023 Dec; 101(24):e2472-e2482. PubMed ID: 37652699
[TBL] [Abstract][Full Text] [Related]
20. COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis.
Holmstroem RB; Nielsen OH; Jacobsen S; Riis LB; Theile S; Bjerrum JT; Vilmann P; Johansen JS; Boisen MK; Eefsen RHL; Marie Svane I; Nielsen DL; Chen IM
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36096534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]